| |
Thursday, July 10, 2025 | 10am ET / 7am PT The transition from drug discovery to process development poses significant challenges. Join us for this deep dive into how adopting a collaborative approach between medicinal and process chemistry teams can help address key obstacles and accelerate progress from discovery to early clinical milestones. Register now. 
|
|
Today’s Big NewsJul 1, 2025 |
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now. 
|
|
| By James Waldron Argenx wants to get in on the macrocyclic peptide action, penning a deal worth $1.5 billion in biobucks with Californian biotech Unnatural Products to hunt down “undruggable” targets. |
|
|
|
By Fraiser Kansteiner After taking aim at the United States’ vaccine safety reporting system earlier this year, Robert F. Kennedy Jr. has added a federal vaccine injury compensation program to his list of immunization bugbears. And this time around, the HHS Secretary says he already has a team working on a potential overhaul. |
By Zoey Becker The U.S. Supreme Court ruled to protect a measure of the Affordable Care Act that supports preventative services such as pre-exposure prophylaxis (PrEP) HIV meds, offering good news for Gilead as it launches its long-acting PrEP drug Yeztugo. |
By Conor Hale Medtronic and Philips have re-upped their long-running partnership focused on bundling vital sign sensors together with patient monitoring equipment. |
|
MedTech companies often launch groundbreaking devices, only to face slow adoption due to costly, time-intensive, and difficult-to-scale training. This whitepaper explores how Virtual Reality (VR) is changing that, helping teams engage physicians earlier, accelerate product adoption, and drive stronger commercial outcomes. Download now to learn more. 
|
|
By Zoey Becker The former boy band star was first treated for Type 2 diabetes before being diagnosed with Type 1.5 diabetes, also known as latent autoimmune diabetes in adults, and effectively reaping the benefits of Dexcom's G7 continuous glucose monitor. |
By Angus Liu In a quarterly update, the FDA said it’s evaluating the need for regulatory action on argenx’s Vyvgart Hytrulo after observing a potential signal of “severe worsening” of CIDP. But analysts are brushing off the risk. |
By Darren Incorvaia After several years of development, Processa Pharmaceuticals has determined that the nearest milestone for anticancer asset PCS3117 is too far away. |
By Gabrielle Masson Concentra Biosciences continues to scavenge for struggling biotechs, this time picking up antibody biotech IGM Biosciences for $1.25 per share. |
By Andrea Park As Dry Eye Awareness Month kicks off, Bausch + Lomb is rolling out a new campaign to improve education about the condition. |
By Fraiser Kansteiner As trade pressures and geopolitical uncertainties mount, it’s imperative that the European Union swiftly strengthen and adopt new policies that provide “targeted support for sustainable and resilient manufacturing,” Michal Nitka, chief of Teva’s Europe generics and global over-the-counter businesses, said via email. |
By Conor Hale The company said its Magnetom Flow.Ace system, with its closed circuit and no quench exhaust pipe, only requires 0.7 liters of liquid helium to run. |
By Nick Paul Taylor Oncternal Therapeutics’ ROR1 programs have gone out with a whimper, offloaded to Ho’ola Therapeutics for $3 million upfront as the biotech winds down its operations. |
By Nick Paul Taylor The Peetes have turned Gemtesa promotion into a family business, with former professional quarterback Rodney Peete joining his wife Holly Robinson Peete on the list of brand ambassadors for the overactive bladder drug. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," Teva CEO Richard Francis shares progress on the company’s “Pivot to Growth” strategy and what lies ahead. |
|
|---|
|
|
|
In all the “what if” chatter and fatigue around AI, predictive sales intelligence is a key opportunity that can easily be implemented and scaled to make omnichannel strategies even more potent. Our whitepaper explores the value of this capability, what role it plays in evolving HCP engagement trends, how to implement, and what to look for when engaging new partners and solutions. Download now.
|
|
Whitepaper Presented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
Whitepaper We analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| Deadline Extended: July 2 |
|
| Sheraton Philadelphia Downtown |
|
|
| |
|
